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BACKGROUND: Risk stratification in catecholaminergic polymorphic ventricular tachycardia remains ill defined. Heart rate recovery 
(HRR) immediately after exercise is regulated by autonomic reflexes, particularly vagal tone, and may be associated with symptoms 
and ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Our objective was to evaluate 
whether HRR after maximal exercise on the exercise stress test (EST) is associated with symptoms and ventricular arrhythmias.
METHODS: In this retrospective observational study, we included patients ≤65 years of age with an EST without antiarrhythmic 
drugs who attained at least 80% of their age- and sex-predicted maximal HR. HRR in the recovery phase was calculated as 
the difference in heart rate (HR) at maximal exercise and at 1 minute in the recovery phase (ΔHRR1′).
RESULTS: We included 187 patients (median age, 36 years; 68 [36%] symptomatic before diagnosis). Pre-EST HR and 
maximal HR were equal among symptomatic and asymptomatic patients. Patients who were symptomatic before diagnosis 
had a greater ΔHRR1′ after maximal exercise (43 [interquartile range, 25–58] versus 25 [interquartile range, 19–34] 
beats/min; P<0.001). Corrected for age, sex, and relatedness, patients in the upper tertile for ΔHRR1′ had an odds ratio of 
3.4 (95% CI, 1.6–7.4) of being symptomatic before diagnosis (P<0.001). In addition, ΔHRR1′ was higher in patients with 
complex ventricular arrhythmias at EST off antiarrhythmic drugs (33 [interquartile range, 22–48] versus 27 [interquartile 
range, 20–36] beats/min; P=0.01). After diagnosis, patients with a ΔHRR1′ in the upper tertile of its distribution had 
significantly more arrhythmic events as compared with patients in the other tertiles (P=0.045).
CONCLUSIONS: Catecholaminergic polymorphic ventricular tachycardia patients with a larger HRR following exercise are more 
likely to be symptomatic and have complex ventricular arrhythmias during the first EST off antiarrhythmic drug.
VISUAL OVERVIEW: A visual overview is available for this article.
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Inherited arrhythmia disorders such as catecholamin-ergic polymorphic ventricular tachycardia (CPVT) are an important cause of sudden cardiac death (SCD) 
among young individuals.1 Patients with CPVT have a 
normal 12-lead ECG and a structurally normal heart.2 
However, in the setting of increased sympathetic activ-
ity such as exercise or emotions, these patients display 
progressive ventricular ectopy of escalating com-
plexity that may include bidirectional or polymorphic 
ventricular arrhythmias (VAs) and may lead to SCD.2 
The exercise stress test (EST) is the gold standard to 
establish the diagnosis of CPVT.3 Young age at diag-
nosis, aborted cardiac arrest (ACA), and the complex-
ity of VAs have been identified as predictors of risk of 
arrhythmic events in patients with CPVT.4 However, in 
many patients, the risk of future arrhythmic events can-
not accurately be estimated.
Heart rate behavior during exercise and recovery from 
exercise is mediated chiefly by the balance between 
the two components of the extrinsic autonomic nervous 
system (ANS): the sympathetic and parasympathetic 
branches.5 The ANS has long been known to play a role 
in arrhythmogenesis and cardiac electrical stability.6 This 
was first demonstrated in a study associating SCD in 
postmyocardial infarction patients with reduced heart 
rate variability and baroreflex sensitivity—both measures 
of the ANS.7 A contrary observation was seen in a South 
African founder population of patients with congenital 
long-QT syndrome (LQTS) type 1. Here, subjects with 
strong autonomic reflexes, assessed by baroreflex sensi-
tivity8 and accentuated heart rate recovery (HRR),9 had a 
higher probability of being symptomatic.
Since patients with LQT1 and CPVT both have arrhyth-
mic events under circumstances of increased sympa-
thetic activity, we hypothesized that CPVT patients with 
strong autonomic reflexes may also be at increased risk 
for arrhythmic events. Here, we studied the association 
between HRR and arrhythmic events in patients with CPVT.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Design, Setting, and Population
The study population was derived from the International CPVT 
Registry. This is a retrospective, multicenter cohort study insti-
tuted in 2014 by the Academic Medical Center (Amsterdam, 
the Netherlands), which has included patients with CPVT from 
25 international centers to date. The diagnosis of CPVT is 
based on the clinical phenotype and genetically confirmed by 
the identification of a pathogenic CPVT-associated mutation, 
primarily in the RYR2-encoded ryanodine receptor/calcium 
release channel (CPVT1), according to the expert consen-
sus guidelines.3 All centers received institutional review board 
approval for this type of study.
Nonstandard Abbreviations and Acronyms
ΔHRR1′  absolute difference (Δ) in heart rate 
between the values recorded at the 
peak exercise and those recorded 1 
minute after termination of exercise
ΔHRR2′  absolute difference (Δ) in heart rate 
between the values recorded at the 
peak exercise and those recorded 2 
minute after termination of exercise
AAD antiarrhythmic drug
ACA aborted cardiac arrest
ANS autonomic nervous system
CPVT  catecholaminergic polymorphic ventricu-
lar tachycardia
EST exercise stress test
HR heart rate
HRmax maximum heart rate
HRR@1′ heart rate at the first minute of recovery
HRR@2′  heart rate at the second minute of 
recovery
IQR interquartile range
LQTS long-QT syndrome
OR odds ratio
SCD sudden cardiac death
VA ventricular arrhythmia
VT ventricular tachycardia
WHAT IS KNOWN?
• Risk stratification in catecholaminergic polymorphic 
ventricular tachycardia is ill defined.
• Vagal reflexes, assessed by heart rate recovery fol-
lowing an exercise stress test, are associated with 
the probability of being symptomatic in congenital 
long-QT syndrome type 1.
WHAT THE STUDY ADDS?
• Catecholaminergic polymorphic ventricular tachy-
cardia patients with a higher heart rate recovery at 
the first exercise stress test off antiarrhythmic drugs 
are more likely to have been symptomatic before 
diagnosis.
• Heart rate recovery is higher in catecholaminergic 
polymorphic ventricular tachycardia patients with 
complex ventricular arrhythmias (couplets and non-
sustained ventricular tachycardias) at the first exer-
cise stress test off antiarrhythmic drugs.
• Vagal reflexes assessed through heart rate recov-
ery are associated with symptoms before diagnosis 
and complex ventricular arrhythmias during exercise 
in catecholaminergic polymorphic ventricular tachy-
cardia patients.
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Deidentified clinical and genetic data were recorded on 
specifically designed web-based forms both at baseline evalu-
ation and during follow-up. Detailed information was required 
regarding the first available EST without antiarrhythmic drugs 
(AADs), in particular β-blockers, and the first EST performed on 
the maximal tolerable dose of β-blockers.
For this study, we selected patients from the International 
CPVT Registry who had an EST performed without AAD and 
with available information about the maximum heart rate (HRmax) 
reached during exercise and the heart rate during the first min-
ute of recovery (n=267). Of these, we excluded patients who 
were over the age of 65 years at the time of EST because of 
the known negative correlation between age and vagal reflexes 
in this age group. To guarantee an appropriate chronotropic 
competence and minimize potential confounding factors due 
to different EST protocols used across the study population, 
we excluded patients who did not reach 80% of their predicted 
HRmax (calculated by age and sex). The available 12-lead ECG 
traces of the EST of patients reported to have both complex 
VAs during the EST and either a maximum HR value in the 
higher decile or an HRR value in the lower decile were directly 
inspected. If supraventricular or ventricular arrhythmias were 
found to affect the maximum HR or the recovery HR (impos-
sible to determine the sinus node activity), the patients were 
excluded from the analysis (1 patient with complex VAs and 1 
patient with atrial arrhythmias were excluded; Figure 1).
Symptomatic patients were defined as patients who had 
experienced an arrhythmic syncope or ACA before CPVT was 
diagnosed. Asymptomatic patients had to be at least 15 years 
old at the time of the EST and off AAD. After the EST without 
AAD, we followed the patients until their first arrhythmic event 
after diagnosis or date of last contact. Arrhythmic events during 
follow-up were defined as arrhythmic syncope, ACA, appropri-
ate ICD shock, or SCD.
EST Evaluation
ESTs of the patients included in the present study were per-
formed between April 1995 and March 2017. A multistage 
fatigue-limited EST was performed according to local protocols. 
HR decrease during the recovery phase was calculated as the 
difference (Δ) in HR between the values recorded at peak exer-
cise (HRmax) and those recorded one (HRR@1′) and 2 (HRR@2′) 
minutes after termination of exercise and is abbreviated by 
ΔHRR1′ and ΔHRR2′. HR increase was defined as the differ-
ence between the HR at peak exercise and the pretest HR.
Severity of VAs on the EST was scored according to the 
worst VA noted and was categorized into the following 5 
categories: no VAs, single ventricular premature beats only, 
bigeminal ventricular premature beats, couplets, nonsustained 
ventricular tachycardia (VT), or sustained VT. Couplets, nonsus-
tained VT, and sustained VT were considered complex VAs.
Statistical Analysis
Data were analyzed using IBM SPSS statistics database 
(released 2011, IBM SPSS Statistics for Windows, version 24; 
IBM Corp, Armonk, NY) and with R, version 3.4.3 (The R Project 
for Statistical Computing).
We performed 3 analyses. The first and second analyses 
assessed potential correlations between characteristics of the 
first EST without AAD and the first available EST on the maximal 
tolerable dose of β-blockers and the presence of symptoms 
before these ESTs. The third analysis assessed potential cor-
relations between characteristics of the first EST without AAD 
and the presence of arrhythmic events after this EST.
Clinical parameters are presented for the entire study popu-
lation, as well as for the study population stratified by symp-
tom status. Continuous variables are presented as median 
(interquartile range [IQR]), were inspected for normality of the 
distribution, and compared by the Student t test or the Mann-
Whitney U test where appropriate. Categorical variables are 
expressed as absolute and relative frequencies and were com-
pared with the χ2 test.
ΔHRR had a nonlinear relationship with the occurrence of 
symptoms before diagnosis. Therefore, we dichotomized this 
variable at the upper tertile of its distribution to assess the 
association between ΔHRR and the presence of symptoms. 
Odds ratios (ORs) with 95% CIs were estimated by logistic 
regression. To compensate for possible correlation of charac-
teristics between relatives within a family, generalized estimat-
ing equations with a logit link function and an exchangeable 
correlation structure were applied. Receiver operating charac-
teristic curves were constructed, and the area under the curve 
was used to determine the performance of the ΔHRR in dis-
criminating between symptomatic and asymptomatic cases. 
Sensitivity analyses were performed excluding the RYR2 
p.R420W mutation. We used the Kaplan-Meier method to pro-
vide survival estimates, which were assessed with the log-rank 
test. P<0.05 was considered statistically significant.
RESULTS
Study Population
A total of 187 patients with CPVT from 95 families were 
included in the study (Table 1; Figure 1). The median age 
at the EST without AAD was 36 years (IQR, 19–47). 
Sixty-eight patients (36%) were symptomatic before 
diagnosis: 52 patients (76%) had an arrhythmic syncope 
and 16 patients (24%) an ACA as their worst symptom 
before diagnosis (median age at worst symptom, 14 
years [IQR, 11–20]). Symptomatic patients were more 
often the familial proband (49% versus 8%; P<0.001) 
and were younger at the EST (23 [IQR, 12–39] versus 
40 [IQR, 27–50] years; P<0.001). The vast majority of 
the patients (94.7%) had a CPVT1-causative variant in 
RYR2 (Table I in the Data Supplement).
Heart Rate Recovery During Exercise Testing 
and Risk of Symptoms
Pretest HR, HRmax, and HR at the first ventricular prema-
ture beat were equal between symptomatic and asymp-
tomatic patients (Table 1; Figure 2A). However, HRR 
after the cessation of exercise was different between the 
groups. Symptomatic patients had a lower HRR@1′ (125 
[IQR, 110–147] versus 143 [IQR, 129–154] beats/
min; P<0.001) and HRR@2′ (104 [IQR, 88–123] versus 
120 [IQR, 107–134] beats/min; P<0.001). Significantly 
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higher values of ΔHRR1′ (43 [IQR, 25–58] versus 
25 [IQR, 19–34] beats/min; P<0.001) and ΔHRR2′ 
(66 [IQR, 46–89] versus 49 [IQR, 36–58] beats/min; 
P<0.001) were observed in symptomatic patients (Fig-
ure 2B). Expressed as percentages, symptomatic and 
asymptomatic patients had a ΔHRR1′ decrease of 26% 
and 15% (P<0.001) and a ΔHRR2′ decrease of 40% 
and 28% (P<0.001), respectively.
Within the symptomatic patient group, there were no 
significant differences in ΔHRR1′ or ΔHRR2′ between 
patients who had an arrhythmic syncope and patients 
who had an ACA as their worst symptom before diagno-
sis (data not shown).
To assess the association between ΔHRR1′ and 
symptoms, we dichotomized the ΔHRR1′ value at ≥36 
beats/min, which represented the upper tertile of its dis-
tribution. Indeed, patients in the upper tertile of ΔHRR1′ 
had an increased risk of being symptomatic (OR, 5.0 
[95% CI, 2.6–9.8]; P<0.001). We considered age and sex 
to be potential confounders in the association between 
ΔHRR1′ and symptoms before diagnosis. In addition, 
since some patients were related to each other, we also 
considered relatedness to be a potential confounder. Fol-
lowing adjustment for age, sex, and relatedness, patients 
with a ΔHRR1′ ≥36 beats/min (representing the upper 
tertile of its distribution) still had an OR of 3.6 ([95% 
CI, 1.9–6.9]; P<0.001) of being symptomatic before 
diagnosis compared with patients with a ΔHRR1′ ≤36 
beats/min (area under the curve, 0.74; Figure I in the 
Data Supplement).
Since 39 patients (21%) carried the p.R420W variant 
in RYR2, we performed a sensitivity analysis excluding 
patients with this mutation to see whether the results are 
not driven by this mutation. Results did not differ on the 
univariate analysis (OR, 4.7 [95% CI, 2.3–9.8]; P<0.001) 
or following adjustment for age, sex, and relatedness 
(OR, 3.4 [95% CI, 1.6–7.4]; P<0.0014).
VA Burden and Heart Rate Recovery
Next, we evaluated the relationship between VA burden 
and HRR. Fifty asymptomatic (42%) and 36 symptom-
atic (53%) patients had complex VAs (couplets, non-
sustained VT, or sustained VT) as the worst VA on the 
EST (P=0.19; Table 1). Patients with complex VAs had 
a greater ΔHRR1′ (33 [IQR, 22–48] versus 27 [IQR, 
20–36] beats/min; P=0.01) and ΔHRR2′ (56 [IQR, 
40–76] versus 51 [IQR, 38–60] beats/min; P=0.01; Fig-
ure 3), compared with patients with simple VAs. We then 
stratified patients with complex VAs by symptom status. 
Symptomatic patients with complex VAs had a greater 
ΔHRR1′ (51 [IQR, 33–63] versus 26 [IQR, 19–37] 
beats/min; P<0.001) and ΔHRR2′ (76 [IQR, 57–97] ver-
sus 47 [IQR, 34–61] beats/min; P<0.001) than asymp-
tomatic patients with complex VAs (Figure 4).
EST on Maximal Tolerable Dose of β-Blockers
An EST on the maximum tolerated dose of β-blockers 
was performed in a total of 112 patients (59.9%), and in 
71 of these patients (63.4%), information about HRR@1′ 
was available. Median interval between the baseline EST 
without AAD and the first EST on the maximal toler-
able dose of β-blockers was 2.3 years (IQR, 0.6–5.5). 
The most frequently used β-blockers were metoprolol 
(31.0%) and bisoprolol (29.6%). Table II in the Data Sup-
plement shows the β-blocker dosages.
Symptomatic patients were younger at the EST on 
β-blockers (33 [IQR, 16–45] versus 43 [IQR, 28–50] 
years; P=0.02; Table III in the Data Supplement). We 
Figure 1. Flowchart of the included 
patients.
ΔHRR1′ indicates difference (Δ) in heart 
rate between the values recorded at 
the peak exercise and those recorded 
1 min after termination of exercise; 
AAD, antiarrhythmic drug; CPVT, 
catecholaminergic polymorphic ventricular 
tachycardia; and EST, exercise stress test.
Lieve et al Postexercise Heart Rate Recovery in CPVT
Circ Arrhythm Electrophysiol. 2020;13:e007471. DOI: 10.1161/CIRCEP.119.007471 March 2020 251
did not observe any differences in heart rate profile dur-
ing the EST or at 1 minute (ΔHRR1′, 33 [IQR, 24–44] 
versus 27 [IQR, 21–36] beats/min; P=0.16) or 2 min-
utes (ΔHRR2′, 50 [IQR, 43–63] versus 45 [IQR, 35–52] 
beats/min; P=0.098) in the recovery phase (Table III 
in the Data Supplement). Thirty-five patients (49.3%) 
achieved at least 80% of the predicted maximal heart 
rate, including 12 symptomatic patients (33.3%). In this 
subset, symptomatic patients had a significantly greater 
ΔHRR1′ (40 [IQR, 30–44] versus 25 [IQR, 21–35] 
beats/min; P=0.037) and a significantly greater ΔHRR2′ 
(58 [IQR, 46–68] versus 47 [IQR 36–55] beats/min; 
P=0.023; Table 2; Figure 5).
Arrhythmic Events After Diagnosis
After the first EST off AAD and during a median follow-
up of 3.5 years (IQR, 1.1–7.4), 10 patients (5.3%) experi-
enced an arrhythmic event: 6 patients (3.2%) experienced 
an appropriate implantable cardioverter defibrillator 
shock and 4 (2.1%) had an arrhythmic syncope. Patients 
with a ΔHRR1′ in the upper tertile of its distribution had 
significantly more arrhythmic events (n=7) after diagno-
sis as compared with patients in the combined lower and 
middle tertile (n=3; P=0.045; Figure 6).
DISCUSSION
Our findings, obtained in a relatively large multicenter 
cohort of patients with CPVT, indicate that the magni-
tude of HRR both at 1 and 2 minutes after the cessa-
tion of exercise to at least 80% of maximum predicted 
heart rate identified CPVT patients more likely to 
have been symptomatic before diagnosis (and thus 
before the initiation of AADs). Patients with a large 
ΔHRR1′ were 5× more likely to have been symp-
tomatic before diagnosis. Furthermore, patients with 
a larger ΔHRR1′ and ΔHRR2′ were also more likely 
Table 1. Baseline Characteristics and Results of First EST Off Antiarrhythmic Drugs
All (n=187) Asymptomatic (n=119) Symptomatic (n=68) P Value
Proband 43 (23) 10 (8) 33 (49) <0.001
Female sex 110 (59) 62 (52) 48 (71) 0.021
Age at exercise test, y 36 (19–47) 40 (27–50) 23 (12–39) <0.001
Age at worst symptom, y 14 (11–20) NA 14 (11–20)  
Syncope 52 (28) NA 52 (76)  
ACA 16 (9) NA 16 (24)  
Pretest HR, bpm 76 (66–87), n=181 76 (67–87), n=114 76 (65–86), n=75 0.970
HR at first VPB, bpm (n=135)* 126 (110–140), n=99/135 130 (112–149), n=56/84 120 (108–135), n=43/51 0.113
HRmax 169 (160–179) 168 (157–178) 173 (160–183) 0.074
Percentage of max predicted HR 94 (89–100) 95 (90–100) 92 (87–99) 0.030
Heart rate increase, bpm 93 (79–106) 91 (79–104) 98 (79–111) 0.116
HRR@1′ 137 (121–151) 143 (129–154) 125 (110–147) <0.001
ΔHRR1′ 28 (21–43) 25 (19–34) 43 (25–58) <0.001
%ΔHRR1′ 17 (12–25) 15 (11–20) 26 (15–33) <0.001
HRR@2′ 115 (97–131), n=155 120 (107–134), n=96 104 (88–123), n=59 <0.001
ΔHRR2′ 53 (39–68), n=155 49 (36–58), n=96 66 (46–89), n=59 <0.001
%ΔHRR2′ 32 (24–40), n=155 28 (22–34), n=96 40 (28–49), n=59 <0.001
Worst VA 0.647
No arrhythmia 52 (28) 35 (29) 17 (25)  
VPB 25 (13) 17 (14) 8 (12)  
Bigeminy 24 (13) 17 (14) 7 (10)  
Couplet 34 (18) 21 (18) 13 (19)  
NSVT/VT 52 (28) 29 (24) 23 (34)  
Categorical variables are expressed as absolute and relative frequencies. Continuous variables are expressed as median with IQR. All heart rates are expresses as 
beats per minute. Mann-Whitney U test and Student t test were used to calculate the P value where appropriate. Total numbers are included when they differ from those 
in the overall study group. ΔHRR1′ indicates absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after 
termination of exercise; ΔHRR2′, absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination 
of exercise; %ΔHRR1′, relative difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after termination of exercise; 
%ΔHRR2′, relative difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination of exercise; ACA, aborted 
cardiac arrest; bpm, beats per minute; EST, exercise stress test; HR, heart rate; HRmax, maximum heart rate; HRR@1′, heart rate at the first minute of recovery; HRR@2′, 
heart rate at the second minute of recovery; IQR, interquartile range; max, maximum; max, maximum; NA, not applicable; NSVT, nonsustained ventricular tachycardia; VA, 
ventricular arrhythmia; VPB, ventricular premature beat; and VT, ventricular tachycardia.
*Fifty-two patients did not have any VA on the EST.
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to have complex VAs during the first EST off AAD. 
These results could also be confirmed in the EST on 
a maximal tolerable dose of β-blockers. Finally, in an 
analysis that was unadjusted for potential confound-
ers, patients with a ΔHRR1′ in the upper tertile of its 
distribution (ie, ≥36 beats/min) had significantly more 
arrhythmic events as compared with patients in the 
other tertiles after diagnosis.
Autonomic Reflexes in the General Population
The heart rate changes observed during exercise and 
the recovery from exercise are mediated by the inter-
play between the sympathetic and the parasympathetic 
limbs of the ANS. Therefore, the EST can be consid-
ered as a simple and economic tool to indirectly assess 
cardiac autonomic reflexes. Based on studies in ani-
mals and healthy humans, the reactivation of the vagal 
nerve is considered the main force of these heart rate 
changes during the first 4 minutes of the recovery from 
exercise.10
In stark contrast to the observations in this CPVT 
cohort in this present study, multiple associations 
between an increased risk of SCD and reduced vagal 
activity or increased sympathetic activity have been 
identified over the years. Clinical studies in different set-
tings consistently showed that a lower ∆HRR1′ was an 
independent predictor of both cardiovascular and all-
cause mortality in middle-aged individuals.11,12 The Paris 
Prospective Study was the largest study to assess the 
relationship between heart rate profile during exercise 
and recovery from exercise and a risk for lethal arrhyth-
mias.13 During a 23-year follow-up period, the authors 
found a 2-fold increase in the risk of sudden death 
among those with a ∆HRR1′ in the lowest quintile (<25 
beats/min) as compared with the highest quintile (>40 
beats/min). The underlying mechanism of this associa-
tion remains largely elusive.
Figure 2. Exercise test parameters without antiarrhythmic drugs. 
Comparison of heart rates (HRs) in symptomatic and asymptomatic patients at different points of exercise testing without antiarrhythmic drugs 
(A) and ΔHRR1′ and ΔHRR2′ (B). Mann-Whitney U test and Student t test were used to calculate P where appropriate. ΔHRR1′ indicates 
absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after termination of exercise; 
ΔHRR2′, absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination of 
exercise; bpm, beats per minute; HRR@1′, heart rate at the first minute of recovery; and HRR@2′, heart rate at the second minute of recovery.
Figure 3. Comparison between ΔHRR1′ and ΔHRR2′ for patients with simple and complex ventricular arrhythmias.
Mann-Whitney U test and Student t test were used to calculate P where appropriate. ΔHRR2′, absolute difference (Δ) in heart rate between 
the values recorded at the peak exercise and those recorded 2 min after termination of exercise; and bpm, beats per minute.
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Autonomic Reflexes in Inherited Arrhythmia 
Disorders
Due to the well-documented influences of the ANS on 
arrhythmogenesis and cardiac electrical stability, there 
is a strong rationale to assess autonomic reflexes in 
inherited arrhythmia disorders such as congenital 
LQTS and CPVT.
In 2008, Schwartz et al8 assessed the impact of the 
ANS in a South African founder population harboring the 
KCNQ1-A341V mutation causing LQT1. LQT1 is caused 
by loss-of-function mutations in the KCNQ1-encoded 
Kv7.1 potassium channel, which provides the slowly acti-
vating delayed rectifier current (IKs).
14 The authors sug-
gested that strong autonomic reflexes, assessed through 
baroreflex sensitivity, may be detrimental in the setting of 
an intrinsically increased cardiac susceptibility to both cat-
echolamines and abrupt heart rate changes. In a subse-
quent study, the authors were able to replicate this finding 
using a simpler clinical tool: HRR.9 In this study, ∆HRR1′ 
was also assessed in LQTS patients with preserved 
IKs (LQTS types 2 and 3), and no differences between 
symptomatic and asymptomatic patients were observed. 
Finally, they found a good correlation between baroreflex 
sensitivity, determined by the phenylephrine method, and 
∆HRR1′ with a similar ability to predict the risk of life-
threatening arrhythmias (area under the curve>0.70).9
While the suggested proarrhythmogenic mechanism 
in LQT1 is through the effects of sympathetic activation 
on IKs,
9 in CPVT, the proarrhythmogenic diastolic calcium 
leakage from the sarcoplasmic reticulum becomes more 
pronounced in the setting of high sympathetic tone, 
ultimately resulting in delayed afterdepolarizations that 
may lead to triggered arrhythmias. At the end of exer-
cise, there is an instantaneous rebound of vagal reflexes 
while abundant catecholamines are still in the heart. 
This increases the heterogeneity of recovery periods, 
which may confer increased susceptibility for reentrant 
arrhythmias (VT and fibrillation).15 In addition, the higher 
the sympathetic activation during exercise, the higher 
the heart rate will be at peak exercise. The amount of 
heart rate increase at peak, combined with the strength 
of vagal reflexes, will determine the delta and thereby 
the greatest disparity in the recovery period. Interestingly, 
and probably related to the concept just expressed, sup-
pression of the vagal activity by atropine had antiarrhyth-
mic effects in Casq2 knockout and RyR2R4496C/+ mice.16 
Since patients with inherited arrhythmia disorders are 
often young and otherwise healthy, the variability in HRR 
mainly reflects a genetic effect,17 leaving physical training 
as the most significant nongenetic confounding factor. 
Indeed, the genetic traits controlling autonomic reflexes 
are inherited independently from the mutations causing 
the inherited arrhythmia disorders and, therefore, may act 
as an independent modifier of arrhythmic risk.
In our study, we focused on those patients who 
reached at least 80% of their predicted HRmax during 
the EST, because the steepness of HRR is influenced 
by exercise intensity and HRmax.
18 The mean HRmax at the 
EST without AAD in our cohort (169 beats/min) was 
similar to HRmax in previously published CPVT popula-
tions19–21 but higher than reported by Crotti et al9 in their 
LQT1 population (145 beats/min). This may reflect the 
fact that CPVT patients are exercised maximally to try to 
Figure 4. The behavior of the ΔHRR1′ and ΔHRR2′ in patients with complex ventricular arrhythmias stratified by symptom status.
Mann-Whitney U test and Student t test were used to calculate P where appropriate. ΔHRR2′, absolute difference (Δ) in heart rate between 
the values recorded at the peak exercise and those recorded 2 min after termination of exercise; and bpm, beats per minute.
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elicit repetitive VAs to determine the arrhythmic risk of 
the patient. This may also explain why the mean values of 
∆HRR1′ that we observed in our cohort are higher than 
those observed in the LQT1 population9 but in line with 
∆HRR1′ in healthy individuals with comparable age and 
exercise intensity.22
We performed a subset analysis in 71 patients in 
whom data on an EST on β-blocker therapy including 
information about the HRR@1′ was available. When we 
selected the patients who had achieved at least 80% 
of the predicted heart rate, we found that symptomatic 
patients had a significantly larger ∆HRR2′ and a trend 
toward a larger ∆HRR1′. Kannankeril et al10 evaluated 
the parasympathetic effects on HRR in healthy subjects 
and concluded that the effects are most pronounced in 
the first 4 minutes of the recovery phase. In addition, 
Sundaram et al23 evaluated the contribution of the sym-
pathetic withdrawal to HRR@1′. In that study, they found 
that β-adrenergic withdrawal is not a significant factor in 
the HRR@1′. These results suggest that EST in the pres-
ence of β-blockers should have no effect on reinstitution 
of vagal tone and, therefore, no effect on HRR as com-
pared with HRR in the absence of AAD. In addition, since 
heart rate declines exponentially after exercise, ΔHRR1′ 
depends on the HRmax achieved and is not an optimal 
marker to assess HRR during submaximal exercise. 
Table 2. Results of First EST While on Maximal β-Blocker Dose
All (n=35) Asymptomatic (n=23) Symptomatic (n=12) P Value
Proband 9 (26) 3 (13) 6 (50) 0.049
Women 22 (63) 12 (52) 10 (83) 0.149
Age at EST, y 40 (26–51) 41 (26–51) 39 (24–45) 0.297
Pretest HR 71 (61–83), n=34 71 (60–83), n=22 73 (61–82) 0.896
HR at first VPB (n=30)* 132 (114–137), n=20/30 132 (119–139), n=12/20 132 (106–136), n=8/10 0.956
HRmax 153 (148–162) 150 (146–161) 161 (155–164) 0.377
Percentage of max predicted HR 88 (84–93) 87 (84–93) 90 (85–94) 0.322
HRR@1′ 125 (113–136) 126 (116–140) 119 (106–127) 0.230
ΔHRR1′ 30 (23–44) 25 (21–35) 40 (30–44) 0.037
%ΔHRR1′ 18 (14–27) 17 (13–20) 25 (19–30) 0.040
HRR@2′ 108 (93–116), n=33 109 (101–116), n=21 97 (83–109) 0.092
ΔHRR2′ 50 (40–59), n=33 47 (36–55), n=21 58 (46–68) 0.023
%ΔHRR2′ 30 (26–38), n=33 28 (24–34), n=21 37 (30–47) 0.020
Categorical variables are expressed as absolute and relative frequencies. Continuous variables are expressed as median with IQR. All heart rates are expressed as 
beats per minute. Mann-Whitney U test and Student t test were used to calculate the P value where appropriate. Total numbers are included when they differ from those 
in the overall study group. ΔHRR1′ indicates absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after 
termination of exercise; ΔHRR2′, absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination 
of exercise; %ΔHRR1′, relative difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after termination of exercise; 
%ΔHRR2′, relative difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination of exercise; EST, exercise 
stress test; HR, heart rate; HRmax, maximum heart rate; HRR@1′, heart rate at the first minute of recovery; HRR@2′, heart rate at the second minute of recovery; IQR, 
interquartile range; VA, ventricular arrhythmia; and VPB, ventricular premature beat.
*Five patients did not have any VA on the EST.
Figure 5. Exercise test parameters on β-blockers. 
Comparison of heart rates in symptomatic and asymptomatic patients at different points of exercise testing on the maximum tolerable dose of 
β-blockers (A) and ΔHRR1′ and ΔHRR2′ (B). Mann-Whitney U test and Student t test were used to calculate P where appropriate. ΔHRR1′ 
indicates absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 1 min after termination of 
exercise; ΔHRR2′, absolute difference (Δ) in heart rate between the values recorded at the peak exercise and those recorded 2 min after termination 
of exercise; bpm, beats per minute; HRR@1′, heart rate at the first minute of recovery; and HRR@2′, heart rate at the second minute of recovery.
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Therefore, it is most likely that the different protocols 
used in our study play a role in these findings.
Clinical Implications
Our findings have important clinical implications. We 
were able to demonstrate that HRR in the EST with-
out AAD is associated with the presence of arrhythmic 
events before the diagnosis (and thus before the initia-
tion of medical therapy) and the severity of EST-induced 
VAs in a large cohort of CPVT patients. Considering 
the fact that ≈42% of the asymptomatic patients had 
an EST with complex VAs despite never having expe-
rienced an arrhythmic event, our data may be a use-
ful tool for refined risk stratification. Additionally, at a 
comparable intensity of exercise, HRR is a reproduc-
ible measurement in the same subject.24 For example, 
in asymptomatic genotype-positive relatives, the pres-
ence of strong vagal tone in the absence of VAs during 
the first EST could be an argument to be more aggres-
sive with β-blocker therapy than in those without strong 
vagal activation post-exercise.
Limitations of the Study
Due to the retrospective nature of the study, not all 
parameters were available for all patients. In a relatively 
large proportion of patients in the International CPVT 
Registry, an EST off AAD or HRR parameters at EST off 
AAD were not available for analysis. Patients with miss-
ing HRR parameters at EST off AAD were significantly 
younger on the EST without AAD and more often symp-
tomatic. Therefore, a selection bias cannot be excluded. 
Due to the multicenter and retrospective nature of the 
study, different types of EST and recovery protocols were 
used. In addition, we cannot fully exclude that in some 
patients the EST was terminated due to VAs rather than 
due to fatigue. However, we only included patients who 
were exercised to at least 80% of their maximal predicted 
heart rate to account for the different exercise protocols 
and the possibility of a submaximal EST. A large propor-
tion of the patients (77%) include family members of the 
familial proband. These patients are typically diagnosed 
through cascade screening and are, therefore, diagnosed 
at a relatively old age. This patient group may manifest 
Figure 6. Comparison in arrhythmic events after the exercise stress test without antiarrhythmic drugs of upper tertile ΔHRR1′ 
vs rest group.
Kaplan-Meier curves displaying arrhythmic events after the exercise stress test without antiarrhythmic. ΔHRR1′ indicates difference (Δ) in heart 
rate between the values recorded at the peak exercise and those recorded 1 min after termination of exercise; AAD, antiarrhythmic drug; and 
EST, exercise stress test.
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with a milder phenotype with less arrhythmic risk com-
pared with the proband who often present at a younger 
age. However, our population likely represents the gen-
eral CPVT population because disease severity may have 
been overestimated in the earlier cohorts.2 Finally, due to 
the low number of arrhythmic events during follow-up in 
the subset of patients analyzed, we were unable to build 
a multivariable model for predictors of arrhythmic events 
after diagnosis.
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